Corneal Confocal Microscopy in Neurological Research: Impacts on Multiple Sclerosis
The systematic review indicates that corneal confocal microscopy (CCM) effectively shows group-level corneal nerve loss in diabetic peripheral neuropathy (DPN). However, its diagnostic performance for individual cases varies, particularly in multiple sclerosis, where evidence is labeled as less robust and requiring further investigation.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
Understanding the diagnostic capabilities of CCM could aid in early detection and monitoring of neurological conditions, but its varied performance highlights the need for complementary assessment methods.
What this does not prove
The performance of CCM is influenced by patient variability and methodology. Additionally, population-level differences cannot confidently lead to individual diagnosis, and challenges in implementing CCM stem from lack of standardization and validated thresholds.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-20
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceCorneal nerve imaging in systemic neuropathy: A minireview of experimental and precision medicine applications. ↗DOI: 10.5493/wjem.126036
Supporting passages (6)
study designThis minireview critically evaluates the role of CCM for early detection, diagnostic testing, prognostic stratification, longitudinal follow-up, and treatment response assessment in systemic neuropathies, particularly diabetic peripheral neuropathy (DPN).
publication date2026-09-20
interventionCorneal confocal microscopy (CCM) is a rapid, noninvasive imaging technique that enables quantitative assessment of the corneal subbasal nerve plexus and has been proposed as a biomarker of peripheral small-fiber damage.
comparatorAt present, CCM should complement rather than replace established clinical, neurophysiological, functional, and pathological assessments, including quantitative sensory testing and skin biopsy when clinically indicated.
findingsEvidence in other neurologic diseases, including Parkinson's disease, multiple sclerosis, and chemotherapy-induced peripheral neuropathy, is less robust.
limitationsCCM is therefore a promising tool for translational research and precision medicine, but population-level differences in corneal nerve parameters should not be interpreted as establishing an individual diagnosis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.